To better address the evolving risk of type 2 circulating vaccine-derived poliovirus (cVDPV2), GPEI partners together with countries are deploying an innovative tool – novel oral polio vaccine type 2 (nOPV2). The vaccine is a modified version of the type 2 monovalent OPV (mOPV2), which clinical trials have shown provides comparable protection against poliovirus while being more genetically stable and less likely to be associated with the emergence of cVDPV2 in low immunity settings. This means that nOPV2 has the potential to be a significant tool to help stop outbreaks more sustainably.

nOPV2 is being deployed under WHO’s Emergency Use Listing procedure (EUL) to enable its rapid field availability. Even after meeting rigorous EUL criteria for safety and immunogenicity, nOPV2’s performance in the field is being closely monitored in line with EUL standards and data collection continues with the ultimate goal of WHO prequalification and full licensure.

Key Resources

GPEI nOPV2-cVDPV2 fact sheet | English | French |

nOPV2 Frequently Asked Questions (FAQs) | English | French | Portuguese | Spanish | Arabic |

nOPV2 technical brief | English |

PATH fact sheet: Advancing novel polio vaccines | English |

Novel oral polio vaccine type 2 (nOPV2) animation video | English | French | Portuguese | Spanish |

WHO Emergency Use Listing procedure infographic | English | French |

Clinical summary for novel oral polio vaccine type 2 (nOPV2) |EnglishFrench | Arabic | Portuguese |

Scientific publications on nOPV2:

WHO PQ Assessment Report on nOPV2 | English | French |

Polio Vaccine – Novel Oral (nOPV) Monovalent type 2 | English |

nOPV2 Overview | English |

Technical brief | English |

Verification Dose Release | English |

nOPV2 Vaccine Management Guidance | English |

nOPV2 Vaccine Handling | English |

nOPV2 Surveillance Guidance | English |

nOPV2 Safety Guidance | English |

nOPV2 AESI guidance | English |

GPEI polio outbreak response training | English |

Introduction of nOPV2 for Polio Outbreak Response: Supervisory manual | English | French |

GPEI position statement: use of the novel oral polio vaccine type 2 in light of shelf-life of 12 months or less | English |

Interim Guidance on the use of Novel Oral Polio Vaccine Type 2 (nOPV2) for the response to Type 2 Circulating Vaccine-Derived Poliovirus (cVDPV2) during the Initial Use Period (Addendum to the Standard Operating Procedures for Response to a Poliovirus Event or Outbreak, version 3. 1) | English | French | Portuguese | Russian |

Novel oral polio vaccine type 2 (nOPV2) Vaccine-Related Event (VRE) Response Plan | English | French | Arabic | Portuguese |

VRE development guidance note for countries | English | French | Portuguese |

UNICEF Strategic C4D Communications Guidance for Outbreak Response including nOPV2 | English |

Programme Advocacy package for cVDPV Outbreak Response and nOPV2 Introduction | English |

Vaccine Misinformation Management Field Guide | English |

Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 4-7 October 2021 |English |

Framework for the Initial Use of nOPV2, endorsed by the SAGE | English | French |

WHO Executive Board decision urging Member States to expedite processes for authorizing the importation and use of nOPV2 on the basis of its emergency use listing – February 2020 | English| French|

SAGE Recommendations – June 2021 Meeting (Weekly Epidemiological Record) – English and French

SAGE Recommendations – October 2020 Meeting (Weekly Epidemiological Record) – English and French

SAGE Recommendations April 2020 Meeting (Weekly epidemiological record) – English and French

SAGE Recommendations, October 2019 Meeting (Weekly epidemiological record) – English and French

Media center

Additional Resources and Updates